← All Ars Pharmaceuticals, INC filings

Ars Pharmaceuticals, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
SPRY
Ars Pharmaceuticals, INC
SCHEDULE: Millennium Entities Report Stake in ARS Pharmaceuticals
Several entities affiliated with Millennium Management have jointly filed a Schedule 13G, reporting beneficial ownership of ARS Pharmaceuticals common stock.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
SCHEDULE: Millennium Management Boosts ARS Pharma Stake to 6.0%
Millennium Management LLC and affiliated entities have reported a 6.0% beneficial ownership stake in ARS Pharmaceuticals, Inc. common stock.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
SCHEDULE: Millennium Management Discloses 5.4% Stake in ARS Pharma
Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, reported a 5.4% passive beneficial ownership stake in ARS Pharmaceuticals, Inc.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
SCHEDULE: Rubric Capital Discloses 6.27% Stake in ARS Pharma
Rubric Capital Management LP and David Rosen have reported a 6.27% beneficial ownership stake in ARS Pharmaceuticals, Inc. common stock.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
SCHEDULE: BlackRock Discloses 5.1% Stake in ARS Pharmaceuticals
BlackRock, Inc. has reported a 5.1% beneficial ownership stake in ARS Pharmaceuticals, Inc. common stock as of December 31, 2025.